GlassScriptPhysician profile
Katherine E Blalock
NPI 1083996177
$2,475.39
in general payments reported to CMS, 2019-2025
26 companies · $234 in 2025
The $234 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $288 · 2020: $227 · 2021: $547 · 2022: $395 · 2023: $466 · 2024: $318 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,018.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,018.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $347.72 | 2019-2024 | |
| Mylan Specialty L.P. | $303.81 | 2021-2024 | Yupelri, Yupelri |
| Astrazeneca Pharmaceuticals LP | $292.97 | 2020-2024 | Airsupra, Farxiga, Breztri |
| Avanir Pharmaceuticals, INC. | $244.51 | 2019-2022 | |
| Amgen INC. | $236.37 | 2019-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $171.12 | 2020-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $144.51 | 2020-2025 | Jardiance, Mounjaro |
| Abbvie INC. | $122.87 | 2021-2025 | Ubrelvy |
| Janssen Pharmaceuticals, INC | $122.54 | 2019 | |
| Viatris Specialty LLC | $50.86 | 2025 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $49.43 | 2025 | |
| Abbott Laboratories | $45.13 | 2022 | |
| Dexcom, INC. | $42.76 | 2023-2024 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $37.99 | 2022-2023 | Livalo, Seglentis |
| Idorsia Pharmaceuticals US INC | $35.10 | 2022-2023 | Quviviq |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $34.30 | 2023-2024 | Eliquis |
| Allergan, INC. | $29.39 | 2020 | |
| Inogen, INC. | $23.52 | 2024 | |
| Seqirus USA INC | $20.97 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.61 | 2023 | Jardiance |
| Radius Health, INC. | $20.32 | 2023 | Tymlos |
| Eisai INC. | $18.61 | 2021 | |
| Antares Pharma, INC. | $17.47 | 2023 | Xyosted, Nocdurna, Tlando |
| Novartis Pharmaceuticals Corporation | $16.57 | 2019 | |
| Exact Sciences Corporation | $14.85 | 2024 | Cologuard Collection Kit |
| Urovant Sciences INC | $11.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Blalock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.